MCID: ANG020
MIFTS: 57

Angiosarcoma

Categories: Cardiovascular diseases, Fetal diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Angiosarcoma

MalaCards integrated aliases for Angiosarcoma:

Name: Angiosarcoma 12 72 55 36 51 14
Hemangiosarcoma 12 41 69

Characteristics:

Orphanet epidemiological data:

55
angiosarcoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0001816
MeSH 41 D006394
NCIt 46 C3088 C9275
Orphanet 55 ORPHA263413
UMLS via Orphanet 70 C0018923
ICD10 via Orphanet 33 C49.9
KEGG 36 H01666

Summaries for Angiosarcoma

Disease Ontology : 12 A malignant Vascular tumor that results_in rapidly proliferating, extensively infiltrating anaplastic cells derives from blood vessels and derived_from the lining of irregular blood-filled spaces.

MalaCards based summary : Angiosarcoma, also known as hemangiosarcoma, is related to liver angiosarcoma and intravascular papillary endothelial hyperplasia. An important gene associated with Angiosarcoma is FLT4 (Fms Related Tyrosine Kinase 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ethiodized oil and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and bone, and related phenotypes are Increased senescence-associated beta-galactosidase protein expression after pRB stimulation and cardiovascular system

Wikipedia : 72 Angiosarcoma is a cancer of the cells that line the walls of blood vessels or lymphatic vessels. The... more...

Related Diseases for Angiosarcoma

Diseases related to Angiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 346)
# Related Disease Score Top Affiliating Genes
1 liver angiosarcoma 33.9 TP53 VIM VWF
2 intravascular papillary endothelial hyperplasia 32.5 VEGFA VIM
3 lymphangiosarcoma 32.4 FLT4 MYC PROX1 VEGFA VWF
4 epithelioid hemangioendothelioma 32.2 FLT1 KDR PECAM1 VEGFA
5 hemangioendothelioma 31.7 FLI1 FLT4 KDR PECAM1
6 lymphedema 30.5 FLT4 KDR PROX1
7 cavernous hemangioma 30.0 KDR PECAM1 VIM
8 pyogenic granuloma 29.8 TEK VEGFA
9 pneumothorax 29.8 KDR MUC1 VIM
10 benign breast phyllodes tumor 29.8 KIT VIM
11 leiomyosarcoma 29.6 KIT TP53 VIM
12 hemangioma 29.4 FLT4 KDR PECAM1 PROX1 TEK VEGFA
13 malignant peripheral nerve sheath tumor 29.4 KIT MUC1 TP53 VIM
14 perivascular epithelioid cell tumor 29.4 KIT MUC1 VIM
15 gastrointestinal stromal tumor 29.2 KIT TP53 VEGFA VIM
16 cystadenocarcinoma 29.0 MUC1 TP53 VEGFA VIM
17 adenocarcinoma 28.9 KDR KIT MUC1 TP53 VEGFA
18 epithelioid sarcoma 28.8 KRT8 MUC1 VIM
19 ovarian cancer 28.6 KDR MUC1 MYC TP53 VEGFA
20 breast cancer 26.5 FLT1 FLT4 KDR KIT KRT8 MUC1
21 breast angiosarcoma 12.3
22 spleen angiosarcoma 12.2
23 thyroid angiosarcoma 12.2
24 pediatric angiosarcoma 12.2
25 aorta angiosarcoma 12.2
26 skin angiosarcoma 12.2
27 angiosarcoma of the scalp 12.2
28 prostate angiosarcoma 12.2
29 gallbladder angiosarcoma 12.1
30 mediastinum angiosarcoma 12.0
31 ovarian angiosarcoma 12.0
32 conventional angiosarcoma 12.0
33 radiation induced angiosarcoma of the breast 12.0
34 central nervous system angiosarcoma 12.0
35 superior vena cava angiosarcoma 11.9
36 bone angioendothelial sarcoma 11.2
37 pseudoangiomatous stromal hyperplasia 10.8
38 hemifacial spasm 10.5 FLT4 VEGFA
39 lymphatic malformations 10.5 FLT4 PROX1
40 glomeruloid hemangioma 10.5 FLT1 VEGFA
41 gorham's disease 10.5 FLT4 PROX1
42 hepatic angiomyolipoma 10.4 KIT MYC
43 large cell medulloblastoma 10.4 MYC VIM
44 radiation proctitis 10.4 KDR PECAM1 VEGFA
45 mast-cell sarcoma 10.4 KIT VIM
46 angiokeratoma circumscriptum 10.4 FLT1 KDR VEGFA
47 hydrocele 10.4 FLT4 PECAM1 VEGFA
48 acute hemorrhagic leukoencephalitis 10.4 FLT1 KDR VEGFA
49 infiltrating angiolipoma 10.4 VEGFA VWF
50 retinal vascular disease 10.3 FLT1 KDR VEGFA

Graphical network of the top 20 diseases related to Angiosarcoma:



Diseases related to Angiosarcoma

Symptoms & Phenotypes for Angiosarcoma

GenomeRNAi Phenotypes related to Angiosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.8 FLT1 KIT TEK

MGI Mouse Phenotypes related to Angiosarcoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 VWF PROX1 FLI1 MYC KDR FLT1
2 hematopoietic system MP:0005397 10.32 VWF KIT PROX1 FLI1 MYC KDR
3 homeostasis/metabolism MP:0005376 10.31 VWF KRT8 FLT4 PROX1 MYC KIT
4 cellular MP:0005384 10.3 VWF PECAM1 PROX1 FLI1 MYC KIT
5 immune system MP:0005387 10.29 VWF KRT8 KIT FLT4 PROX1 FLI1
6 embryo MP:0005380 10.28 KIT FLT4 FLI1 MYC KDR FLT1
7 growth/size/body region MP:0005378 10.26 KRT8 FLT4 FLI1 MYC KIT KDR
8 mortality/aging MP:0010768 10.25 VWF KRT8 FLT4 PROX1 FLI1 MYC
9 digestive/alimentary MP:0005381 10.2 VWF KRT8 FLT4 PROX1 MYC KIT
10 muscle MP:0005369 10.18 FLT4 PROX1 FLI1 MYC KDR FLT1
11 liver/biliary system MP:0005370 10.16 KIT FLT4 PROX1 FLI1 MYC KDR
12 nervous system MP:0003631 10.11 VWF PROX1 FLI1 MYC KIT KDR
13 normal MP:0002873 9.91 FLT4 PROX1 MYC KIT KDR FLT1
14 no phenotypic analysis MP:0003012 9.87 VWF FLT4 MYC KIT KDR VEGFA
15 reproductive system MP:0005389 9.76 VIM KRT8 FLT4 MYC KIT FLT1
16 respiratory system MP:0005388 9.5 VIM PECAM1 KIT KDR VEGFA TP53
17 vision/eye MP:0005391 9.23 VIM KIT KDR FLT1 TP53 PROX1

Drugs & Therapeutics for Angiosarcoma

Drugs for Angiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2
23 Etoposide phosphate Phase 3,Phase 2
24 Anti-Infective Agents Phase 3,Phase 2
25 Antirheumatic Agents Phase 3,Phase 2,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
28 Antibodies Phase 3,Phase 2,Phase 1
29 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
30 Immunoglobulins Phase 3,Phase 2,Phase 1
31 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
32 Anti-Allergic Agents Phase 3
33 Antipruritics Phase 3
34 Dermatologic Agents Phase 3
35 Gastrointestinal Agents Phase 3
36 Histamine Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39
Serotonin Phase 3 50-67-9 5202
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Gemcitabine Approved Phase 2 95058-81-4 60750
48
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
49
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
50
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551

Interventional clinical trials:

(show top 50) (show all 63)

# Name Status NCT ID Phase Drugs
1 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
10 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA Recruiting NCT02979899 Phase 3 Votrient
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma Unknown status NCT01055028 Phase 2 Paclitaxel in combination with Bevacizumab
17 Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery Unknown status NCT00874874 Phase 2 sorafenib tosylate
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
20 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Completed NCT01623869 Phase 2
21 Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery Completed NCT00217607 Phase 2 paclitaxel
22 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
23 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
27 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
28 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
29 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
30 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
31 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
33 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
34 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
35 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
36 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
37 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
38 Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Recruiting NCT03331250 Phase 2 Eribulin
39 Evaluation of Votrient in Angiosarcoma Recruiting NCT02212015 Phase 2 Pazopanib + Paclitaxel
40 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Recruiting NCT01462630 Phase 2 pazopanib hydrochloride
41 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Recruiting NCT02048722 Phase 2 regorafenib
42 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
43 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
44 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
45 Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Active, not recruiting NCT01303497 Phase 2 Paclitaxel;Bevacizumab
46 Bevacizumab in Treating Patients With Angiosarcoma Active, not recruiting NCT00288015 Phase 2
47 A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Active, not recruiting NCT01140737 Phase 2 Axitinib
48 A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Active, not recruiting NCT01975519 Phase 1, Phase 2 TRC105 and Pazopanib
49 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2 temsirolimus
50 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Tria Not yet recruiting NCT02732678 Phase 1, Phase 2 PROPRANOLOL

Search NIH Clinical Center for Angiosarcoma

Cochrane evidence based reviews: hemangiosarcoma

Genetic Tests for Angiosarcoma

Anatomical Context for Angiosarcoma

MalaCards organs/tissues related to Angiosarcoma:

38
Breast, Liver, Bone, Lung, Endothelial, Thyroid, Spleen

Publications for Angiosarcoma

Articles related to Angiosarcoma:

(show top 50) (show all 922)
# Title Authors Year
1
Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: A care-compliant case report and literature review. ( 29384853 )
2018
2
Contrast uptake in primary hepatic angiosarcoma on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the hepatobiliary phase. ( 29399290 )
2018
3
Cutaneous Angiosarcoma of the Eyelid Mimicking Morbihan Disease. ( 29329133 )
2018
4
Eosinophilic Pustular Folliculitis Associated with Cutaneous Angiosarcoma. ( 29271395 )
2018
5
Treatment of cutaneous angiosarcoma of the scalp and face in Chinese patients: local experience at a regional hospital in Hong Kong. ( 29326400 )
2018
6
Radiation-induced angiosarcoma of the omentum diagnosed by laparoscopy: A case report. ( 29399355 )
2018
7
Primary cardiac angiosarcoma: A case report. ( 29349900 )
2018
8
First report of proton beam therapy for breast angiosarcoma from the prospective PCG registry. ( 29303019 )
2018
9
Bilateral ovarian angiosarcoma arising from the mature cystic teratomas - A case report and review of the literature. ( 29227858 )
2018
10
Cutaneous angiosarcoma in a patient with systemic sclerosis: First case from India. ( 29376512 )
2018
11
Angiosarcoma following treatment of basal cell carcinoma: a report of two cases. ( 29345300 )
2018
12
Impact of specialist management on survival from radiation-associated angiosarcoma of the breast. ( 29405251 )
2018
13
Primary Spleen Angiosarcoma With Concomitant Hepatic Hemangiomas on 18F-FDG PET/CT. ( 29356748 )
2018
14
Clinical and Pathologic Features of Primary Angiosarcoma of the Kidney. ( 29383452 )
2018
15
Response: Cardiac magnetic resonance in cardiac angiosarcoma-Which contrast-enhancement pattern is typical? ( 29409130 )
2018
16
Cardiac magnetic resonance in cardiac angiosarcoma-Which contrast-enhancement pattern is typical? ( 29409131 )
2018
17
Primary ovarian angiosarcoma in a 12- year -old girl: a case report of an exceptional localization in a context of limited resources country. ( 28852325 )
2017
18
Image Gallery: A case of cutaneous giant angiosarcoma treated successfully with electrochemotherapy. ( 28833026 )
2017
19
HSP90 inhibition in angiosarcoma. ( 28833016 )
2017
20
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. ( 28641307 )
2017
21
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. ( 29138703 )
2017
22
Angiosarcoma Developing in an Arteriovenous Fistula after Kidney Transplantation. ( 28845318 )
2017
23
Innovative application of intraoperative laser-assisted fluorescence angiography in resection of an angiosarcoma of the scalp. ( 28943057 )
2017
24
Large nose angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol. ( 28833588 )
2017
25
Breast angiosarcoma without radiation history, putatively associated with subclinical lymphedema: A case report and review of the Japanese literature. ( 28543441 )
2017
26
Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. ( 28794852 )
2017
27
Atypical Presentation of Radiation-Associated Breast Angiosarcoma: A Case Report and Review of Literature. ( 29249796 )
2017
28
Aspergillus Terreus Brain Abscess Complicated by Tension Pneumocephalus in a Patient with Angiosarcoma. ( 28070116 )
2017
29
Aggressive Indeterminate Dendritic Cell Tumor Mimicking Scalp Angiosarcoma. ( 28966519 )
2017
30
Metastatic Primary Angiosarcoma of the Breast: Can We Tame It the Metronomic Way. ( 28900339 )
2017
31
Survivin: A novel marker and potential therapeutic target for human angiosarcoma. ( 28845553 )
2017
32
Clinicopathological features of breast angiosarcoma: A 16-years single-institution experience. ( 28704748 )
2017
33
Primary breast angiosarcoma - a single institution experience from a tertiary cancer center in SouthA India. ( 29286911 )
2017
34
Multifocal angiosarcoma of the gastrointestinal tract:a case report. ( 28883296 )
2017
35
Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma. ( 28895418 )
2017
36
Primary Epithelioid Angiosarcoma of Lung: Radiologic and Clinicopathologic Correlation. ( 28900554 )
2017
37
Cutaneous angiosarcoma: a current update. ( 28916596 )
2017
38
Angiosarcoma of the Adrenal Gland Treated Using a Multimodal Approach. ( 27920990 )
2017
39
Primary breast angiosarcoma: a rare presentation of rare tumor - case report. ( 28855848 )
2017
40
Occult Cardiac Angiosarcoma Presenting as Cardiac Tamponade. ( 28864382 )
2017
41
Primary Hepatic Angiosarcoma Mimicking Multifocal Liver Abscess with Disseminated Intravascular Coagulation and Hemoperitoneum. ( 28680781 )
2017
42
Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma. ( 28052681 )
2017
43
Primary breast angiosarcoma in young women from the same geographic region in a short period of time: Only a coincidence or an increased risk? ( 28597488 )
2017
44
18F-FDG PET/CT of Secondary Epithelioid Angiosarcoma of the Proximal Femur in a Patient With Polyostotic Fibrous Dysplasia. ( 28806239 )
2017
45
Cutaneous Radiation-associated Breast Angiosarcoma: Radicality of Surgery Impacts Survival. ( 28267696 )
2017
46
Angiomatoid fibrous histiocytoma of the scalp mimicking cutaneous angiosarcoma in incisional biopsy containing CD31-positive histiocytes: A potential histopathological pitfall. ( 28370384 )
2017
47
MYC amplification in angiosarcomas arising in the setting of chronic lymphedema of morbid obesity. ( 27686553 )
2017
48
A successful insertion of PICC in patient with cardiac angiosarcoma and neoplasty of right atrium and pacemaker: A case report. ( 29390474 )
2017
49
Salvage Hypofractionated Radiotherapy in a Progressive Radiation-Induced Angiosarcoma: A Case Report. ( 29387515 )
2017
50
Clinical outcomes in breast angiosarcoma patients: A rare tumor with unique challenges. ( 29205355 )
2017

Variations for Angiosarcoma

ClinVar genetic disease variations for Angiosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh37 Chromosome 12, 25398262: 25398262

Expression for Angiosarcoma

Search GEO for disease gene expression data for Angiosarcoma.

Pathways for Angiosarcoma

Pathways related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 FLT1 FLT4 KDR KIT MUC1 MYC
2
Show member pathways
13.65 FLT1 FLT4 KDR KIT MYC TEK
3
Show member pathways
13.58 FLT1 FLT4 KDR KIT MYC TEK
4
Show member pathways
13.44 FLT1 FLT4 KDR KIT MYC TEK
5
Show member pathways
13.27 KIT MUC1 MYC TEK TP53 VEGFA
6
Show member pathways
13.18 FLT1 FLT4 KDR KIT TEK VEGFA
7
Show member pathways
12.92 FLT1 FLT4 KDR KIT TEK
8
Show member pathways
12.82 FLT1 FLT4 KDR VEGFA VWF
9 12.77 FLT4 KIT MYC TP53 VEGFA
10
Show member pathways
12.63 FLT1 FLT4 KDR KIT TEK VEGFA
11 12.52 FLT1 FLT4 KDR KIT MYC TEK
12 12.45 MYC TP53 VEGFA VIM
13
Show member pathways
12.43 FLT1 FLT4 KDR TP53
14
Show member pathways
12.43 FLT1 FLT4 KDR KIT MYC TEK
15
Show member pathways
12.38 FLT1 FLT4 KDR TP53
16
Show member pathways
12.33 FLT1 FLT4 KDR VEGFA
17
Show member pathways
12.3 FLT1 FLT4 KDR VEGFA
18 12.24 KDR MYC TP53 VEGFA
19 12.19 FLI1 FLT1 MYC TP53
20
Show member pathways
12.09 FLT1 FLT4 KDR MYC TEK TP53
21 12.04 FLT1 FLT4 KDR KIT TEK
22 12.03 KDR PECAM1 TP53 VEGFA
23 11.98 FLT1 KDR TP53 VEGFA
24 11.98 KDR MYC PROX1 VEGFA VIM
25 11.94 MYC TP53 VIM
26
Show member pathways
11.92 FLT1 KDR VEGFA
27 11.86 MUC1 MYC TP53 VEGFA VIM
28 11.85 FLT1 TEK VEGFA
29
Show member pathways
11.81 KIT MYC VEGFA
30
Show member pathways
11.81 FLT1 FLT4 KDR VEGFA
31 11.79 FLT1 TEK VEGFA
32
Show member pathways
11.74 FLT1 FLT4 KDR KIT
33 11.68 MYC TP53 VEGFA
34 11.62 KIT MYC TP53
35
Show member pathways
11.59 FLT1 FLT4 KDR KIT
36 11.49 MYC TP53 VEGFA
37 11.28 FLT1 KDR VEGFA
38 11.18 FLT1 FLT4 KDR MYC VEGFA
39 11.11 FLT1 FLT4 KDR PECAM1 PROX1 TEK
40 11.05 FLT1 KDR TEK VEGFA
41 10.95 FLT1 FLT4 KDR KIT TEK VIM
42
Show member pathways
10.83 FLT1 FLT4 KDR VEGFA

GO Terms for Angiosarcoma

Cellular components related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 FLT1 FLT4 KDR KIT KRT8 MUC1

Biological processes related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 KIT MYC TP53 VEGFA VIM
2 positive regulation of cell migration GO:0030335 9.91 FLT1 KDR KIT VEGFA
3 angiogenesis GO:0001525 9.89 FLT1 FLT4 KDR TEK VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.88 FLT4 KDR TEK VEGFA
5 positive regulation of cell proliferation GO:0008284 9.87 FLT1 FLT4 KDR KIT MYC PROX1
6 positive regulation of angiogenesis GO:0045766 9.86 FLT1 KDR TEK VEGFA
7 platelet degranulation GO:0002576 9.85 PECAM1 VEGFA VWF
8 cellular response to hypoxia GO:0071456 9.84 MYC TP53 VEGFA
9 protein autophosphorylation GO:0046777 9.83 FLT1 FLT4 KDR KIT TEK
10 positive regulation of MAPK cascade GO:0043410 9.81 FLT1 FLT4 KDR KIT
11 peptidyl-tyrosine phosphorylation GO:0018108 9.8 FLT1 FLT4 KDR KIT TEK
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 KIT PECAM1 VEGFA
13 positive regulation of MAP kinase activity GO:0043406 9.79 FLT1 KIT VEGFA
14 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.78 FLT1 FLT4 KDR VEGFA
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 FLT1 KDR KIT TEK
16 ovarian follicle development GO:0001541 9.75 KIT MYC VEGFA
17 positive regulation of cell cycle GO:0045787 9.74 MYC PROX1 TP53
18 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.72 FLT1 KIT TEK
19 positive regulation of focal adhesion assembly GO:0051894 9.7 KDR TEK VEGFA
20 megakaryocyte development GO:0035855 9.67 FLI1 KIT
21 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.67 MUC1 TP53
22 embryonic hemopoiesis GO:0035162 9.67 KDR KIT
23 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.66 FLT1 VEGFA
24 cell migration involved in sprouting angiogenesis GO:0002042 9.65 KDR VEGFA
25 positive regulation of leukocyte migration GO:0002687 9.65 TP53 VEGFA
26 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.65 FLT1 FLT4 KDR KIT TEK
27 positive regulation of positive chemotaxis GO:0050927 9.64 KDR VEGFA
28 lymph vessel development GO:0001945 9.64 FLT4 PROX1
29 lymphangiogenesis GO:0001946 9.63 FLT4 PROX1
30 positive regulation of phospholipase C activity GO:0010863 9.63 FLT1 KIT
31 positive regulation of protein kinase C signaling GO:0090037 9.62 FLT4 VEGFA
32 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.6 KDR VEGFA
33 vascular endothelial growth factor signaling pathway GO:0038084 9.54 FLT1 FLT4 KDR
34 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.46 FLT1 FLT4 KDR VEGFA
35 positive regulation of endothelial cell proliferation GO:0001938 9.35 FLT4 KDR PROX1 TEK VEGFA
36 positive regulation of endothelial cell migration GO:0010595 9.02 FLT4 KDR PROX1 TEK VEGFA
37 phosphorylation GO:0016310 10.07 FLT1 FLT4 KDR KIT TEK
38 protein phosphorylation GO:0006468 10.04 FLT1 FLT4 KDR KIT TEK
39 negative regulation of apoptotic process GO:0043066 10.01 FLT4 KDR MYC TEK TP53 VEGFA

Molecular functions related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 FLT1 FLT4 KDR KIT TEK
2 protein kinase activity GO:0004672 9.8 FLT1 FLT4 KDR KIT TEK
3 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.67 FLI1 MYC PROX1 TP53
4 protein tyrosine kinase activity GO:0004713 9.65 FLT1 FLT4 KDR KIT TEK
5 protease binding GO:0002020 9.63 KIT TP53 VWF
6 growth factor binding GO:0019838 9.46 FLT1 FLT4 KDR TEK
7 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.43 KDR KIT
8 vascular endothelial growth factor-activated receptor activity GO:0005021 9.13 FLT1 FLT4 KDR
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FLT1 FLT4 KDR KIT TEK
10 protein binding GO:0005515 10.2 FLI1 FLT1 FLT4 KDR KIT KRT8

Sources for Angiosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....